Effect of fluconazole on the growth and adhesion of Candida albicans in the presence of antineoplastic agents

Journal of Basic Microbiology

Volumn 39, Issue 5-6, 1999, Pages 305-310

  Fekete Forgács, Katalin ^a   Kis, Bernadett ^a   Nagy, Gábor ^b   Lenkey, Béla ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID; ANTINEOPLASTIC AGENT; EPITHELIUM CELL; ETOPOSIDE; FLUCONAZOLE; FUNGAL GROWTH; GROWTH INHIBITION; METHOTREXATE; MICROBIAL ADHESION; SURFACE;

CANDIDA ALBICANS;

EID: 0033398053     PISSN: 0233111X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-4028(199912)39:5/6<305::aid-jobm305>3.0.co;2-%23     Document Type: Article

References (26)

1. AKOVA, M., AKALIN, H. E., UZUN, O., HAYRAN, M., TEKUZMAN, G., KANSU, E., ASLAN, S. and TELATAR, H., 1994. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. Clin. Infect. Dis., 18, 298-304.
2. BODET, C. A., JORGENSEN, J. H. and DRUTZ, D. J., 1985. Antibacterial activities of antineoplastic agents. Antimicrob. Agents Chemother., 28, 437-439.
3. BODEY, G. P., 1988. Fungal infections in cancer patients. Ann. N. Y. Acad. Sci., 544, 431-442.
4. BRAGA, P. C., Dal SASSO, M., MACI, S., PIATTI, G., DANNHORN, D. R. and BOHN, M., 1995. Inhibition of Candida albicans adhesiveness to human buccal and vaginal cells by sub-inhibitory concentrations of rilopirox. Arzneim.-Forsch./Drug Res., 45, 84-87.
5. BRAGA, P. C., MACI, S., DAL SASSO, M. and BOHN, M., 1996. Experimental evidences for a role of subinhibitory concentrations of rilopirox, nystatin and fluconazole on adherence of Candida spp. to vaginal epithelial cells. Chemotherapy, 42, 259-265.
6. CLIFT, R. A., 1984. Candidiasis in the transplant patient. Am. J. Med., 77, 34-38.
7. CUTLER, J. E., 1991. Putative virulence factors of Candida albicans. Ann. Rev. Microbiol., 45, 187-218.
8. DAROUICHE, R. O., 1998. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin. Infect. Dis., 26, 259-274.
9. DARWAZEH, A. M. G., LAMEY, P. J., LEWIS, M. A. O. and SAMARANAYAKE, L. P., 1991. Systemic fluconazole therapy and in vitro adhesion of Candida albicans to human buccal epithelial cells. J. Oral Pathol. Med., 20, 17-19.
10. FEKETE-FORGÁCS, K., GYÜRE, L. and LENKEY B, 1999. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. (accepted for publication) Mycoses, 11-12.
11. FUKAZAWA, Y. and KAGAYA, K., 1997. Molecular bases of adhesion of Candida albicans. J. Med. Vet. Mycol., 35, 87-99.
12. GHANNOUM, M. A., 1992. Candida albicans antifungal-resistant strains: studies on adherence and other pathogenicity related characteristics. Mycoses. 35, 131-139.
13. GIERINGER, J. H., WENZ, A. F., JUST, H. M. and DASCHNER, F. D., 1986. Effect of 5-fluorouracil, mitoxantrone, methotrexate, and vincristine on the antibacterial activity of ceftriaxone, ceftazidime, cefotiam, piperacillin, and netilmicin. Chemotherapy, 32, 418-424.
14. GILLIS, M. C. (Editor-in Chief), 1996. Compendium of Pharmaceuticals and Specialties, ed 31. pp. 508-509, 856-865, Ottawa, Canadian Pharmaceutical Association.
15. HAMILTON-MILLER, J. M. T., 1984. Antimicrobial activity of 21 anti-neoplastic agents. Br. J. Cancer, 49, 367-269.
16. ISSEL, B. F. and CROOKE, S. T., 1979. Etoposide (VP-16-213). Cancer Treat. Rev., 6, 107-124.
17. KLEIN, R. S., HARRIS, C. A., SMALL, C. B., MOLL, B., LESSER, M. and FRIEDLAND, G. H., 1984. Oral candidiasis in high-risk patients as the initial manifestation of the aquired immunodeficiency syndrome. N. Engl. J. Med., 311, 354-358.
18. LAKE, D. E., KUNZWEILER, J., BEER, M., BUELL, D. N. and ISLAM, M. Z., 1996. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy, 42, 308-314.
19. MEURMAN, J. H., PYRHÖNEN, S., TEERENHOVI, L. and LINDQVIST, C., 1997. Oral sources of septicaemia in patients with malignancies. Oral Oncol., 33, 389-397.
20. MEURMAN, J. H., TORKKO, H. and PYRHÖNEN, S., 1991. Antineoplastic agents inhibit the growth of Streptococcus mutans and Streptococcus sanguis in vitro. Oral Microbiol. Immunol., 6, 177-181.
21. MICHEL, J., JACOBS, J. Y. and SACKS, T., 1979. Bactericidal effect of combinations of antimicrobial drugs and antineoplastic antibiotics against Gram-negative bacilli. Antimicrob. Agents Chemother., 16, 761-766.
22. MOODY, M. R., MORRIS, M. J., YOUNG, V. M., MOYE, L. A., STCHIMPFF, S. C. and WIERNIK, P. H., 1978. Effect of two cancer chemotherapeutic agents on the antibacterial activity of three antimicrobial agents. Antimicrob. Agents Chemother., 14, 737-742.
23. ODDS, F. C., 1988. Candida and Candidosis, ed 3. London, Bailliere Tindall.
24. REEF, S. E. and MAYER, K. H., 1995. Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin. Infect. Dis., 21, 99-102.
25. SANDVEN, P., 1990. Laboratory identification and sensitivity testing of yeast isolates. Acta Odontol. Scand., 48, 27-36.
26. SONIS, S. T., SONIS, A. L. and LIEBERMAN, A., 1978. Oral complications in patients receiving treatment for malignancies other than of the head and neck. J. Am. Dent. Assoc., 97, 468-472.